Guardant Health (GH) Tops Q4 EPS by 46c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Guardant Health (GH) PT Lowered to $130 at Stifel
February 24, 2022 6:57 AM ESTStifel analyst Daniel Arias lowered the price target on Guardant Health (NASDAQ: GH) to $130.00 (from $160.00) while maintaining a Buy rating.
The analyst commented, "GH finished the year with a good beat and an initial 2022 outlook that includes solid clinical volume growth expectations... More
Guardant Health (GH) PT Lowered to $110 at Cowen
February 24, 2022 6:42 AM ESTCowen analyst Max Masucci lowered the price target on Guardant Health (NASDAQ: GH) to $110.00 (from $170.00) while maintaining an Outperform rating.
The analyst commented, "With the ECLIPSE trial readout expected in mid-2022, GH is approaching another landmark event for the field of cancer... More
